16024-60-5 Usage
Description
3,6,9,12-Tetraoxatridecanoic acid, also known as m-PEG4-CH2COOH, is a PEG (polyethylene glycol) linker containing a terminal carboxylic acid. This terminal carboxylic acid can react with primary amine groups in the presence of activators, such as EDC or HATU, to form a stable amide bond. The hydrophilic PEG spacer increases solubility in aqueous media, making it a versatile compound for various applications. It is typically a white or off-white solid and is considered a useful research chemical.
Uses
Used in Research and Development:
3,6,9,12-Tetraoxatridecanoic acid is used as a research chemical for various applications in the field of chemistry and biochemistry. Its ability to form stable amide bonds with primary amine groups makes it a valuable tool for the synthesis of new compounds and the modification of existing ones.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3,6,9,12-Tetraoxatridecanoic acid is used as a building block for the development of new drugs and drug delivery systems. The hydrophilic PEG spacer can improve the solubility and bioavailability of drug molecules, potentially enhancing their therapeutic effects.
Used in Material Science:
3,6,9,12-Tetraoxatridecanoic acid can be utilized in the development of new materials with specific properties, such as improved solubility, stability, or biocompatibility. The PEG linker can be incorporated into polymers or other macromolecules to tailor their characteristics for various applications.
Used in Diagnostics:
The ability of 3,6,9,12-Tetraoxatridecanoic acid to form stable amide bonds can be exploited in the development of diagnostic tools, such as immunoassays or biosensors, where stable and specific binding of target molecules is crucial for accurate detection and measurement.
Overall, 3,6,9,12-Tetraoxatridecanoic acid is a versatile compound with a wide range of potential applications across various industries, including research and development, pharmaceuticals, material science, and diagnostics. Its unique properties, such as the ability to form stable amide bonds and the hydrophilic PEG spacer, make it a valuable tool for the development of new products and technologies.
Check Digit Verification of cas no
The CAS Registry Mumber 16024-60-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,0,2 and 4 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 16024-60:
(7*1)+(6*6)+(5*0)+(4*2)+(3*4)+(2*6)+(1*0)=75
75 % 10 = 5
So 16024-60-5 is a valid CAS Registry Number.
16024-60-5Relevant articles and documents
Effect of Oligoethylene Chains on the Formation of Photoresponsive Nanotubes by Azobenzene Dyad
Saito, Takuho,Yagai, Shiki
, p. 2475 - 2478 (2020)
Azobenzene dyad 1 possessing hydrophobic side chains has previously been reported to assemble into toroidal nanostructures, which can further stack to afford nanotubes in nonpolar media. In this study, amphiphilic dyad 2 was synthesized to obtain nanotubes with the hydrophilic interior. Dyad 2 directly assembled into nanotubes without forming isolatable toroidal nanostructures. UV light irradiation to the nanotubes resulted in monomerization by trans→cis photoisomerization, but following reconstruction by visible light irradiation afforded amorphous films, suggesting a kinetic trap of trans-2 by residual cis-2 through co-aggregation.
NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS
-
Page/Page column 54-55, (2020/08/28)
The present invention relates to novel triterpene derivatives of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and ring are as defined herein. The invention also relates to novel triterpene derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.
A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS
-
, (2019/07/17)
The present invention relates to the conjugation of a tubulysin analog compound to a cell-binding molecule with branched/side-chain linkers for having better delivery of the conjugate compound and targeted treatment of abnormal cells. It also relates to a branched-linkage method of conjugation of a tubulysin analog molecule to a cell-binding ligand, as well as methods of using the conjugate in targeted treatment of cancer, infection and autoimmune disease.
